Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies

Pemigatinib is a potent inhibitor of the fibroblast growth factor receptor (FGFR) family of receptors that is approved for the treatment of cholangiocarcinoma with FGFR2 fusion or other rearrangements. Data from a first‐in‐human clinical study were used to assess the potential for pemigatinib to pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Xiaohua, Ji, Tao, Liu, Xiang, Chen, Xuejun, Yeleswaram, Swamy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929369/
https://www.ncbi.nlm.nih.gov/pubmed/34951522
http://dx.doi.org/10.1002/prp2.906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929369/
https://www.ncbi.nlm.nih.gov/pubmed/34951522
http://dx.doi.org/10.1002/prp2.906

Ejemplares similares